Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Virax Biolabs Group Ltd. Class A ( (VRAX) ).
Virax Biolabs Group Ltd. convened its 2024 Annual Meeting of Shareholders but initially failed to achieve quorum, resulting in an adjournment. The reconvened meeting on December 19, 2024, reached quorum, allowing shareholders to approve all proposed measures, including the appointment of auditors, election of directors, and the implementation of the 2024 Equity Incentive Plan. These approvals are poised to support the company’s governance and strategic objectives moving forward.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Ltd. operates in the biotechnology sector, focusing on the development of diagnostic products and solutions. The company is based in the United Kingdom and is involved in innovative healthcare solutions targeting infectious diseases.
YTD Price Performance: 19.86%
Average Trading Volume: 1,808,980
Technical Sentiment Consensus Rating: Buy
For a thorough assessment of VRAX stock, go to TipRanks’ Stock Analysis page.
